



Mezzion Pharma Co. Ltd
Attention: Dean Park, M.B.A., Chief Executive Officer
WG Kim, Executive Director
1 Bridge Plaza, Suite 1008
Fort Lee, New Jersey 07024

Re: Submission of Clinical Trial Information Pursuant to 42 U.S.C. 282(j)
FDA Reference Number: CDER-2024-108
NCT03013751

Dear Mr. Park and Mr. Kim:

On March 14, 2025, the Food and Drug Administration (FDA) sent Mezzion Pharma Co. Ltd, a Notice of Noncompliance regarding noncompliance with the requirements to submit clinical trial information to the ClinicalTrials.gov data bank. At this time, it appears that your company has addressed the issues raised in the FDA's letter.

Sincerely,

{See appended electronic signature page}

Laurie Muldowney, M.D.
Deputy Director
Office of Scientific Investigations
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LAURIE B MULDOWNNEY
01/28/2026 05:51:07 AM